I think this is not a bad result. They are seeking from CXS that a generic diagnostic test be developed before approval is given so that patients can be accurately identified with the mutation.
I always thought that a diagnostic test would be needed anyway to roll Omapro out.
- Forums
- ASX - By Stock
- 7-1 thumbs down - more testing needed
I think this is not a bad result. They are seeking from CXS that...
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)